The Oncodetect test is tumor-informed, tracking up to 200 circulating tumor DNA (ctDNA) variants. It delivers simple “detected” or “not detected” results alongside quantitative data to guide adjuvant therapy decisions, monitor treatment response, and detects up to 200 ctDNA variants identifying signs of colorectal cancer recurrence up to two years earlier than imaging.
The commercial launch of Oncodetect, announced 22 April, came in line with Exact Sciences’ previously communicated timeline for a second-quarter 2025 rollout, but notably without securing Medicare coverage.
Key Takeaways
Exact Sciences launched its tumor-informed Oncodetect MRD test for colorectal cancer, but lacks Medicare reimbursement, which limits early commercial potential.
Exact Sciences has officially entered the molecular residual disease (MRD) testing market with the launch of Oncodetect, expanding its precision...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.
EU countermeasures against US tariffs suggest medtech categories exported to the EU could be targeted for tariffs. MedTech Europe and the German IVDs industry have stressed the negative effects this would have on patient care.
The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.
